Straits Times Index
3,341.10 +2.16 (+0.06%) Nikkei
38,365.03 -472.43 (-1.22%) Hang Seng
18,541.22 +97.11 (+0.53%) FTSE 100
8,232.04 -30.71 (-0.37%) Bitcoin USD
71,093.08 +2,009.42 (+2.91%) CMC Crypto 200
1,485.64 +38.49 (+2.67%)
Navamedic ASA (0FDB.L)
| Previous close | 37.20 |
| Open | 0.00 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 134 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.30 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Navamedic ASA: Minutes of Annual General Meeting
The Annual General Meeting of Navamedic ASA was held today at 09:00 CEST. All items on the agenda were resolved in accordance with the board of directors' proposals and the nomination committee's recommendations. A copy of the minutes from the Annual General Meeting is attached to this notice and will also be made available on the Company's webpage www.navamedic.com.
- PR Newswire
Navamedic ASA: Renewed contract for delivering antibiotics to Norwegian hospitals
Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, has received confirmation of an extension of its contract with The Norwegian Hospital Procurement Trust (Sykehusinnkjøp HF) for continued delivery of antibiotics to Norwegian hospitals. The contract runs to 31 January 2027.
- PR Newswire
Navamedic ASA: Broad launch for Eroxon® in Sweden today
Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies has launched Eroxon® in Sweden. Eroxon® is clinically proven and considered a breakthrough in treatment of erectile dysfunction for men and will be the first non-prescription treatment for erectile dysfunction in the Swedish market.
